Skip to main content

7 Result(s)

within F Cottini Remove this filter

and

  1. Article

    Open Access

    Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma

    While clinical benefit of the proteasome inhibitor (PI) bortezomib (BTZ) for multiple myeloma (MM) patients remains unchallenged, dose-limiting toxicities and drug resistance limit the long-term utility. The E...

    E Malek, M A Y Abdel-Malek, S Jagannathan, N Vad, R Karns, A G Jegga, A Broyl… in Leukemia (2017)

    Download PDF (2226 KB) View Article

  2. No Access

    Article

    Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma

    Histone deacetylase (HDAC) inhibitors have been extensively investigated as therapeutic agents in cancer. However, the biological role of class IIa HDACs (HDAC4, 5, 7 and 9) in cancer cells, including multiple...

    S Kikuchi, R Suzuki, H Ohguchi, Y Yoshida, D Lu, F Cottini, J Jakubikova… in Leukemia (2015)

  3. Article

    Open Access

    Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma

    Immunomodulatory drugs (IMiDs) thalidomide, lenalidomide (Len) and pomalidomide trigger anti-tumor activities in multiple myeloma (MM) by targetting cereblon and thereby impacting IZF1/3, c-Myc and IRF4. Histo...

    T Hideshima, F Cottini, H Ohguchi, J Jakubikova, G Gorgun, N Mimura… in Blood Cancer Journal (2015)

    Download PDF (1188 KB) View Article

  4. No Access

    Article

    Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

    R Suzuki, T Hideshima, N Mimura, J Minami, H Ohguchi, S Kikuchi, Y Yoshida… in Leukemia (2015)

  5. No Access

    Article

    Histone deacetylase 3 as a novel therapeutic target in multiple myeloma

    Histone deacetylases (HDACs) represent novel molecular targets for the treatment of various types of cancers, including multiple myeloma (MM). Many HDAC inhibitors have already shown remarkable antitumor activ...

    J Minami, R Suzuki, R Mazitschek, G Gorgun, B Ghosh, D Cirstea, Y Hu, N Mimura… in Leukemia (2014)

  6. No Access

    Article

    Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs

    Small-molecule multi-targeted cyclin-dependent kinase (CDK) inhibitors (CDKIs) are of particular interest due to their potent antitumor activity independent of p53 gene alterations. P53 deletion is associated wit...

    D Cirstea, T Hideshima, L Santo, H Eda, Y Mishima, N Nemani, Y Hu, N Mimura… in Leukemia (2013)

  7. Article

    Risk factors for acute renal failure in trauma patients

    To elucidate the risk factors for the development of acute renal failure (ARF) in severe trauma.

    G. Vivino, M. Antonelli, M. L. Moro, F. Cottini, G. Conti… in Intensive Care Medicine (1998)

    Download PDF (608 KB)